In contrast, administration of the SDF1-A antibody concomitant to the injection of exogenous Lin−/Sca1+ cells (Figure 4B) prevented any reduction in infarct volume (35±15 versus 31±22%; stroke+SDF1-A antibody+placebo vs stroke+SDF1-A antibody+ Lin−/Sca1+ cells, p = NS). This evidence concerns the gene CXCL12 and Stroke.